血脂康对比辛伐他汀治疗中国成人原发性高脂血症疗效和安全性的分析

Comparison of the efficacy and safety of Xuezhikang and simvastatin in the treatment of primary hyperlipidemia in Chinese adults

目的系统评价血脂康和辛伐他汀治疗中国成人原发性高脂血症的疗效及安全性。方法用计算机检索维普、万方、中国知网、中国生物医学文献、Web of Science、PubMed、EMbase、Cochrane Library等数据库,筛选出应用血脂康(试验组)和辛伐他汀(对照组)治疗中国成人原发性高脂血症的随机对照试验(RCTs),用改良Jadad评分量表对纳入文献进行质量评价,用RevMan 5.3和Stata 12.0软件对2组患者总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)及药物不良反应(ADR)发生率等指标进行Meta分析。结果最终纳入7篇RCTs文献,共656例患者。Meta分析结果显示,2组患者的TC降低水平[加权均数差(WMD)=-0.03 mmol·L^(-1)]、TG降低水平(WMD=-0.03 mmol·L^(-1))、LDL-C降低水平(WMD=0.03 mmol·L^(-1))、HDL-C升高水平(WMD=0 mmol·L^(-1))比较,差异均无统计学意义(均P>0.05)。试验组的ADR发生率低于对照组,差异有统计学意义[比值比(OR)=0.24,P<0.05]。结论血脂康降低TC、TG和LDL-C,升高HDL-C的疗效与辛伐他汀相当,但安全性更高。

Objective To systematically evaluate the efficacy and safety of Xuezhikang and simvastatin in the treatment of primary hyperlipidemia in Chinese adults.Methods Technology Journal Database,WanFang Database,China Knowledge Network Database,China Biology Medicine disc,Web of Science,PubMed,EMbase,Cochrane Library and other databases were retrieved by computers to screen out the randomized controlled trials(RCTs)of Xuezhikang(treatment group)and simvastatin(control group)in the treatment of primary hyperlipidemia in Chinese adults.Modified Jadad scale was used to evaluate the quality of the included literature.Meta-analysis of the levels of total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),triglyceride(TG)and the incidence of adverse drug reactions(ADR)were conducted by using Rev Man 5.3 and Stata 12.0 statistical software.Results A total of 7 RCTs were included,involving 656 patients.The results of Meta-analysis showed that there were no statistical differences in the decrease of TC level[mean difference(WMD)=-0.03 mmol·L^(-1)],TG level(WMD=-0.03 mmol·L^(-1)),LDL-C level(WMD=0.03 mmol·L^(-1))and the increase of HDL-C level(WMD=0 mmol·L^(-1)),the differences were not statistically significant(all P>0.05).The incidence of ADR[odd ratio(OR)=0.24,P<0.05]was lower in the treatment group,with statistical significance.Conclusion The results of this study indicated that the therapeutic efficacy of Xuezhikang in the decrease of TC,TG,LDL-C level and in the increase of HDL-C level was similar to that of simvastatin,but with less adverse events.